Sargent Bickham Lagudis’s QVC Group Inc Series A QVCGA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-92
Closed -$13K 1145
2022
Q2
$13K Hold
92
﹤0.01% 668
2022
Q1
$22K Hold
92
﹤0.01% 590
2021
Q4
$35K Hold
92
﹤0.01% 520
2021
Q3
$47K Hold
92
﹤0.01% 457
2021
Q2
$60K Hold
92
﹤0.01% 421
2021
Q1
$54K Hold
92
﹤0.01% 427
2020
Q4
$50K Hold
92
﹤0.01% 426
2020
Q3
$33K Sell
92
-3
-3% -$1.42K ﹤0.01% 440
2020
Q2
$44K Buy
95
+66
+228% +$25.8K ﹤0.01% 372
2020
Q1
$9K Buy
+29
New +$10.4K ﹤0.01% 577
2019
Q3
Sell
-29
Closed -$17K 793
2019
Q2
$17K Hold
29
﹤0.01% 528
2019
Q1
$23K Hold
29
﹤0.01% 497
2018
Q4
$28K Hold
29
﹤0.01% 445
2018
Q3
$31K Hold
29
﹤0.01% 436
2018
Q2
$30K Hold
29
﹤0.01% 434
2018
Q1
$36K Hold
29
﹤0.01% 412
2017
Q4
$34K Hold
29
﹤0.01% 426
2017
Q3
$33K Hold
29
﹤0.01% 432
2017
Q2
$35K Hold
29
﹤0.01% 414
2017
Q1
$28K Hold
29
﹤0.01% 442
2016
Q4
$28K Hold
29
﹤0.01% 420
2016
Q3
$28 Hold
29
﹤0.01% 435
2016
Q2
$36K Hold
29
0.01% 384
2016
Q1
$36K Buy
+29
New +$35.3K 0.01% 410

Other funds holding QVCGA

Sargent Bickham Lagudis's QVCGA Position: Q3 2022 in Review

Sargent Bickham Lagudis sold out of QVC Group Inc Series A (QVCGA) in Q3 2022, closing a stake of 92 shares — an estimated $13K sold.

Sargent Bickham Lagudis first reported a position in QVCGA in Q1 2016 and held it in 24 quarters. The position peaked at $60K in Q2 2021. 296 funds tracked by Wall St. Rank hold QVCGA as of Q3 2022.

  • Sargent Bickham Lagudis reported no remaining QVC Group Inc Series A position as of Q3 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 92 QVC Group Inc Series A shares in Q3 2022, an estimated $13K.
  • Sargent Bickham Lagudis first reported a position in QVC Group Inc Series A in Q1 2016 and held it in 24 quarters.
  • Sargent Bickham Lagudis's QVC Group Inc Series A position peaked at $60K in Q2 2021.
  • 296 funds tracked by Wall St. Rank held QVC Group Inc Series A as of Q3 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2022, filed 27 Oct 2022.